Chemotherapy: a double-edged sword in cancer treatment Nafiseh BehranvandFarzad NasriReza Falak Review 05 August 2021 Pages: 507 - 526
Correction to: Chemotherapy: a double‑edged sword in cancer treatment Nafiseh BehranvandFarzad NasriReza Falak Correction 28 August 2021 Pages: 527 - 527
A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma Anneloes van DuijnKarin J. WillemsenWalbert J. Bakker Original Article Open access 15 July 2021 Pages: 529 - 540
Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer Elgin HoffmannFrank PaulsenFranziska Eckert Original Article Open access 16 July 2021 Pages: 541 - 552
Transcriptomic signatures of tumors undergoing T cell attack Aishwarya GokuldassAimilia SchinaMarco Donia Original Article 17 July 2021 Pages: 553 - 563
Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma Tomoya MizunoTakao KamaiKen-Ichiro Yoshida Original Article Open access 18 July 2021 Pages: 565 - 578
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors Da Hyun KangChaeuk ChungJeong Eun Lee Original Article Open access 18 July 2021 Pages: 579 - 588
Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma Masahiro OhiraRyuichi HottaHideki Ohdan Original Article 19 July 2021 Pages: 589 - 599
Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq Hongkai ZhuangXinming ChenBaohua Hou Original Article 19 July 2021 Pages: 601 - 612
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21 Jaya Lakshmi ThangarajMinh-Trang Thi PhanJe-Jung Lee Original Article 20 July 2021 Pages: 613 - 625
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody Tamara Mateu-AlberoRaquel Juárez-SánchezCarlos Cuesta-Mateos Original Article 23 July 2021 Pages: 627 - 636
Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer Hui YuPing ChenBei Zhang Original Article 23 July 2021 Pages: 637 - 644
ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas Houshi XuAnke ZhangMeiqing Lou Original Article 27 July 2021 Pages: 645 - 660
Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection Xiuxing ChenZiming DuYuhong Li Original Article 28 July 2021 Pages: 661 - 674
A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma Yajing ZhangYujie ZhuYe Zhang Original Article 03 August 2021 Pages: 675 - 688
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia Xian ZhangJunfang YangPeihua Lu Original Article 07 August 2021 Pages: 689 - 703
The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells Pin-Jui KungTing-Yu LaiChih-Yuan Lee Original Article Open access 10 August 2021 Pages: 705 - 718
Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials Thierry LandreGregoire JusteauBoris Duchemann Original Article 10 August 2021 Pages: 719 - 726
Effect of HLA genotype on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle-invasive bladder cancer Mizuki KobayashiNobuhiro FujiyamaMasaki Shiota Original Article 11 August 2021 Pages: 727 - 736
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression Hiroshi TakumidaHidehito HorinouchiYuichiro Ohe Original Article Open access 14 August 2021 Pages: 737 - 746
An immune-related prognostic signature for thyroid carcinoma to predict survival and response to immune checkpoint inhibitors Pu WuWei SunHao Zhang Original Article 16 August 2021 Pages: 747 - 759